“Increasing demand for natural phospholipids and growth in the cosmetics industry, coupled with abundant raw material availability will create growth prospects for phospholipids market players through the projection period 2022-2032,” says an Future Market Insights analyst.
The global phospholipids market is projected to reach a valuation of US$ 3,037.1 Mn in 2022. Increasing application of phospholipids in the cosmetics sector due to rise in demand for natural phospholipids is expected to propel the sales at 7.6% CAGR, enabling the market reach a valuation of US$ 6,292.0 Mn in 2032.
Rising demand for natural phospholipids to be used in natural cosmetics owing to the high inclination towards natural skin products, along with various health benefits offered by phospholipids in nutraceuticals and infant formulas, will continue pushing sales in the phospholipids market.
Abundant availability of raw materials such as sunflower, rapeseeds, milk, corn etc., and versatility of phospholipids in wide end use applications is contributing to the growth of the phospholipids market. Besides this, increasing frequency in new product launching from the key players, is expected to continue pushing sales of phospholipids.
As per FMI’s regional analysis, US is anticipated to dominate the global phospholipids market. Growth can be attributed to consumer investments on personal care products especially in skin care products, and to presence of prominent manufacturers, forecasting a huge demand for the same in the coming years.
United States Phospholipids Market Analysis
The United States is a key country for demand, having witnessed a CAGR of 5.5%, with an absolute dollar opportunity of US$ 1.3 Billion and a forecasted 2032 market size of US $2.8 Billion at a CAGR of 7.7%. The FDA assigns a GRAS affirmation for lecithin. In June 2022, Croda International Plc announced an agreement with the USA government for the expansion of manufacturing capacity for lipid systems used in novel drug systems. Under this agreement, the USA government will provide US$ 75 Million and Croda will invest US$ 58 Million for the building of Croda’s lipid facility in the USA.
This amount was awarded as a joint award from BARDA, or the Biomedical Research and Development Authority (which is part of the Office of the Assistant Secretary for Preparedness and Response within the USA Department of Health and Human Services) and the JPEO-CBRND or the USA Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defence in partnership with the ACC JCRD or the Army Contracting Command’s Joint COVID Response Division.
Key Takeaways:
- By product type, natural phospholipids is expected to account for more than 63.7% of total phospholipids market share in 2022.
- Sales of phospholipids applied in nutraceuticals is anticipated to hold about 43.7% of the total phospholipids market share in 2022.
- The U.S. is anticipated to hold a dominant share of 80.2% of the North America phospholipids market in 2022.
- China will remain as a lucrative market, creating an incremental opportunity of US$ 331.1 Mn in 2032.
- Germany is projected to account for 18.8% of the Europe phospholipids market share in 2032.
- China and Japan will hold 9.0% and 4.9% of the global phospholipids market share respectively in 2032.
Competitive Landscape
Phospholipids providers are focused on increasing the production of their products to meet demand in widespread applications. The key companies operating include Archer Daniels Midland Company, Croda International Plc, Bunge Ltd., Cargill, Inc., Kewpie Corporation, Lasenor Emul SL, Lecico GmbH, Lipoid GmbH, Sime Darby Unimills B.V. SojaProtein, Stern-Wywiol Gruppe, VAV Life Sciences Pvt. Ltd., and Wilmar International Ltd.
Some of the recent development in Phospholipids are as follows:
In June 2022, Germany’s LECICO GmbH announced the launching of a soy-sourced phospholipid in the form of phosphatidylcholine. The product was named LIPAMINE PC 30 P IP and was intended for use as a nutraceutical for functional food formulations, as well as an excipient in pharmaceutical and liposomes.
In June 2022, Evonik Industries announced an agreement with the USA government for the expansion of its capacity to manufacture lipids for use in mRNA therapies both in and beyond COVID vaccines.
